Grants

awarded

The METAvivor Research Program was established in 2009 with the specific goal of funding stage IV metastatic breast cancer research to one day, end death from metastatic breast cancer (MBC). The following list includes current and past grant recipients along with their progress reports.

Mick Edmonds, PhD, MS

UAB School of Medicine

Presented In Memory of Kristin Todd

A novel strategy targeting SRC tyrosine kinase for breast cancer metastasis

Colt Egelston, PhD

City of Hope

Presented In Memory of Angie Powell by Northwest Arkansas Metsquerade

Bispecific monoclonal antibodies for treatment of advanced breast cancer

DORRAYA EL-ASHRY, PhD

University of Minnesota School of Medicine

Eliminate breast cancer metastasis by targeting the tumor microenvironment

DAVID ENTENBERG, PHD

Albert Einstein College of Medicine

Presented by #LightUpMBC Ambassador Team, in loving memory of Jessica Moore and all lives lost too soon to MBC

Quantifying and Controlling Tumor Cell Re-Dissemination in Metastatic Breast Cancer

Andrew Ewald, PhD

Johns Hopkins University, School of Medicine

Presented In Memory of Avis Halberstadt, Co-Founder of Metavivor

Targeting the survival pathways required by established breast cancer metastases

XU FENG, PhD

University of Alabama at Birmingham

Development of Targeted Drugs for Treating Breast Cancer Bone Metastasis

Barbara Fingleton, PhD

Vanderbilt University

Presented In Memory of Destiny Rivera and Stephanie Sunday by Orlando Metsquerade

Tumor targeting of an immune super-activator in male and female metastatic breast cancer

MICHAEL FLISTER, PhD

Medical College of Wisconsin

Personalized Therapy for Curing Metastatic Breast Cancer

Jeremy Force, DO, MA

Duke University

Presented In Memory of Kristie Godwin Rolan by Triangle Metsquerade

Discovery and validation of putative oncogenic ROS1 alterations in breast cancer

Heide L. Ford, PhD

University of Colorado School of Medicine

Understanding the Role of miR106b-25 in Breast Cancer Associated Metastasis: A potential new metastasis therapy

Jamie Fornetti, BA, PhD

Huntsman Cancer Institute, University of Utah

Presented by Abbey Rapoport

Novel RON Inhibitors for the Treatment of Metastatic Breast Cancer

Monica Fornier, MD

Memorial Sloan Kettering Cancer Center

Presented in memory of Mrs. Holli Hoelscher Simon

A pilot study of the efficacy and safety of the sclerostin-inhibitor romosozumab as a bone-modifying agent for patients with metastatic breast cancer to bones, and osteoporosis or osteopenia with high risk of fracture